CRISPR Therapeutics (NASDAQ:CRSP) Earns Neutral Rating from Analysts at Credit Suisse Group

Research analysts at Credit Suisse Group started coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) in a research note issued to investors on Thursday, The Fly reports. The brokerage set a “neutral” rating and a $78.00 price target on the stock. Credit Suisse Group’s price objective indicates a potential upside of 50.12% from the company’s previous close.

Several other research firms have also recently issued reports on CRSP. Citigroup lowered their target price on shares of CRISPR Therapeutics from $90.00 to $64.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 15th. Stifel Nicolaus lowered their target price on shares of CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. Barclays lowered their target price on shares of CRISPR Therapeutics from $148.00 to $107.00 in a research note on Wednesday, February 16th. Royal Bank of Canada decreased their price target on shares of CRISPR Therapeutics from $117.00 to $95.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 16th. Finally, StockNews.com started coverage on shares of CRISPR Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $125.43.

Shares of CRSP stock opened at $51.96 on Thursday. The stock has a market capitalization of $3.98 billion, a P/E ratio of 11.76 and a beta of 2.02. The firm’s 50 day moving average is $61.09 and its 200 day moving average is $71.89. CRISPR Therapeutics has a 12 month low of $50.54 and a 12 month high of $169.76.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last posted its earnings results on Monday, February 14th. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.74) by ($0.10). CRISPR Therapeutics had a return on equity of 16.21% and a net margin of 41.28%. The firm had revenue of $12.90 million during the quarter, compared to analysts’ expectations of $5.39 million. On average, sell-side analysts anticipate that CRISPR Therapeutics will post -7.69 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC grew its holdings in shares of CRISPR Therapeutics by 160.6% during the 3rd quarter. Larson Financial Group LLC now owns 271 shares of the company’s stock valued at $30,000 after purchasing an additional 167 shares during the last quarter. CI Investments Inc. bought a new stake in CRISPR Therapeutics in the 3rd quarter worth $30,000. Clearstead Advisors LLC grew its holdings in CRISPR Therapeutics by 639.1% in the 3rd quarter. Clearstead Advisors LLC now owns 340 shares of the company’s stock worth $38,000 after acquiring an additional 294 shares during the last quarter. Elkhorn Partners Limited Partnership grew its holdings in CRISPR Therapeutics by 180.0% in the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after acquiring an additional 225 shares during the last quarter. Finally, Kistler Tiffany Companies LLC grew its holdings in CRISPR Therapeutics by 6,250.0% in the 4th quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after acquiring an additional 375 shares during the last quarter. 55.21% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles